product name YK-4-279
Description: YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA). YK-4-279 eliminates cyclin D levels by blocking the interaction of EWS-FLI1 with RHA in EWS-FLI1-containing TC32 cells. YK-4-279 also specifically inhibits ESFT cell growth and induces apoptosis. YK-4-279 also inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells, and further decreases cell motility and invasion.
References: Nat Med. 2009 Jul;15(7):750-6; PLoS One. 2014 Dec 5;9(12):e114260.
366.20
Formula
C17H13Cl2NO4
CAS No.
1037184-44-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 73 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: 51 mg/mL (139.3 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19411814
| In Vitro |
In vitro activity: YK-4-279 eliminates cyclin D levels by blocking the interaction of EWS-FLI1 with RHA in EWS-FLI1-containing TC32 cells. YK-4-279 also specifically inhibits ESFT cell growth and induces apoptosis. YK-4-279 also inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells, and further decreases cell motility and invasion Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In vivo, YK-4-279 (1.5 mg/dose i.p.) inhibits the growth of ESFT xenograft tumors. In mouse model, YK-4-279 selectively prevents prostate cancer growth and metastasis in fusion-positive LNCaP-luc-M6 tumors. |
| Animal model | Nude mice bearing prostate cancer PC3, TC71 or CHP-100 xenografts |
| Formulation & Dosage | Dissolved in DMSO; 1.5 mg/dose; i.p. injection |
| References | Nat Med. 2009 Jul;15(7):750-6; PLoS One. 2014 Dec 5;9(12):e114260. |
